Search clinical trials for: nirmatrelvir

Total 53 results

Pfizer

Not yet recruiting

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Healthy Participants | Biological Availability
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Biological Availability

Belgium
Pfizer

Withdrawn

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

COVID-19 Drug Treatment
Chinese PLA General Hospital

Recruiting

Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease (ESPTCSCKD)

COVID-19 | Renal Insufficiency, Chronic

China
Chinese University of Hong Kong

Completed

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

COVID-19 | Chronic Kidney Disease stage4 | Chronc Kidney Disease Stage 5

Hong Kong
Pfizer

Completed

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

COVID-19

United States, Taiwan, Italy, Canada, Greece
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
Karolinska Institutet
Karolinska University Hospital; Pfizer

Recruiting

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

COVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious Disorder

Sweden
The First Affiliated Hospital of Zhengzhou University
Luoyang Central Hospital; Nanyang Central Hospital; The Fifth People's Hospital... and other collaborators

Completed

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

COVID-19 | Azvudine

China
Universidade do Porto
Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS); Rede... and other collaborators

Active, not recruiting

Effectiveness and Safety of New Oral Antivirals for COVID-19 (ESOA-19)

COVID-19

Portugal
Pfizer

Active, not recruiting

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

COVID-19

Bahrain
Pfizer

Completed

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

Covid-19

Saudi Arabia
Azienda Ospedaliera Universitaria Integrata Verona
Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di...

Completed

Non-inferiority Trial on Treatments in Early COVID-19

COVID-19

Italy
Haukeland University Hospital
University of Oslo; Oslo University Hospital; University of Bergen; Norwegian University... and other collaborators

Recruiting

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (PanoramicNOR)

COVID-19 | SARS-CoV2 Infection | Post COVID-19 Condition, Unspecified

Norway
ANRS, Emerging Infectious Diseases
University Hospital, Geneva

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (OPTICOV)

COVID-19 | Immunodeficiency

Switzerland, France
Pfizer

Suspended

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

COVID-19

United States, United Kingdom, Japan, South Africa, Bulgaria, Puerto Rico, Mexico, Hungary
Unity Health Toronto
Canadian Institutes of Health Research (CIHR); Health Canada

Recruiting

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings (CanTreatCOVID)

COVID-19

Canada
Pfizer

Completed

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

Healthy Volunteers | Pharmacokinetics

Belgium
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Healthy

Egypt
Pfizer

Terminated

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

COVID-19

United States
Pfizer

Withdrawn

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 (EPIC-HOS)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19) | Immunocompromised | Hospitalization | Child, Hospitalized

United States, Bulgaria
Pfizer

Completed

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Healthy Participants

Belgium
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Healthy Participants | Biological Availability

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

COVID-19

United States
Pfizer

Completed

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

COVID-19

Spain, United States, Australia, Canada, Bulgaria, Slovakia, Mexico, Hungary, Brazil
University of Liverpool
University of Southampton; Liverpool University Hospitals NHS Foundation Trust and other collaborators

Active, not recruiting

AGILE (Early Phase Platform Trial for COVID-19)

Covid19

United Kingdom, South Africa
Mclean Hospital

Withdrawn

Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons

Alcohol Dependence | Alcohol Abuse | Heavy Drinking Days

United States
RenJi Hospital

Completed

The Safety of Paxlovid in Hemodialysis Patients With Covid-19 (SPHPS)

Safety Issues

China
Kanecia Obie Zimmerman

Enrolling by invitation

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (RECOVER-VITAL)

Long COVID | Long COVID-19

United States
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis

United States, Canada
University of Oxford

Completed

Mass Screening and Treatment for Reduction of Falciparum Malaria (MSAT)

Plasmodium Falciparum Malaria

Thailand
Peking University
National Natural Science Foundation of China; Institute of reproductive and...

Completed

Effects of Low-dose Complex B-vitamins on Homocysteine and Framingham Risk Score Among Chinese Elderly

Hyperhomocysteinemia

China
Kanecia Obie Zimmerman

Enrolling by invitation

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (RECOVER-VITAL)

Long COVID | Long Covid19

United States, Puerto Rico
University of Oxford

Recruiting

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PLATCOV)

COVID-19

Lao People's Democratic Republic, Thailand, Brazil, Pakistan
University of Melbourne
Australian and New Zealand Intensive Care Research Centre; The Peter Doherty... and other collaborators

Active, not recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT)

SARS-CoV-2 Infection (COVID-19)

Australia
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital; First People's Hospital of Lin'an District; First People...

Recruiting

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Hospitalized Patients

China
Harlan M Krumholz
Pfizer

Active, not recruiting

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults With Long COVID. (PAXLC)

Long COVID

United States
Stanford University
Pfizer

Completed

Paxlovid for Treatment of Long Covid (STOP-PASC)

Long COVID | Post-acute Sequelae of SARS-CoV-2 Infection

United States
Promomed, LLC
Sponsor GmbH

Completed

Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

COVID-19

Russian Federation
Pfizer

Terminated

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

COVID-19

United States, Malaysia, Thailand, Turkey, Spain, Czechia, Poland, Bulgaria, Japan, Korea, Republic of, South Africa, Hungary, Argentina, Brazil, Colombia, Mexico, Puerto Rico, Romania, Slovakia, Ukraine
Shandong Provincial Hospital
Gansu Provincial Hospital; The Affiliated Hospital Of Southwest Medical University and other collaborators

Recruiting

A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

COVID-19

China
Pfizer

Completed

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Hepatic Impairment

United States
Vigonvita Life Sciences

Completed

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

COVID-19

China
Pfizer

Completed

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

Renal Impairment

United States
Pfizer

Completed

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Healthy Participants

United States
Xiangao Jiang

Completed

Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

Omicron Variant of COVID-19

China
China National Center for Cardiovascular Diseases

Active, not recruiting

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery (PEP)

Cardiac Surgery

China
Pfizer

Completed

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Healthy Participants

United States
University of Oxford
Bill and Melinda Gates Foundation; Department for International Development... and other collaborators

Recruiting

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Severe Acute Respiratory Syndrome

Ghana, Indonesia, Nepal, South Africa, United Kingdom, Vietnam, India
Pfizer

Completed

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Healthy Participant

Belgium

3

Subscribe